Novartis India outlined a strategy to double its annualized run rate of ₹650 crore within four to five years, driven by recent acquisitions and a commercial reset. The company acquired the Minipress XL trademark from Pfizer and in-licensed ophthalmology brands to expand its portfolio.

Strategic Shift and Acquisitions

Management announced a shift from a flat revenue trajectory to a growth-focused model centered on six anchor therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology. To support this, the company is building a direct sales force covering approximately 150,000 healthcare practitioners and expanding its distribution network from four cash-and-carry forwarders (C&Fs) to nearly 25.

The most significant recent move was the acquisition of the Minipress XL trademark from Pfizer Inc. Minipress XL holds over 50% market share in the alpha-blocker segment, with reported MAT July '26 revenue of ₹228 crore. The brand has grown at a CAGR of 6.5%, lagging the broader market growth of 9-10%. Management expects an initial EBITDA of roughly ₹90 crore from this asset against an investment of ₹1,250 crore, targeting a payback period of eight to nine years post-synergies.

Additionally, the company in-licensed the ophthalmology portfolio comprising Pagenax and Accentrix from NHPL for an upfront fee of ₹10 crore. This portfolio contributes over ₹100 crore in revenue, providing a platform for further expansion in eye care.

Financial Outlook and Costs

The transition involves significant near-term costs. Quarterly operating expenses are expected to rise from a legacy run rate of ₹10-15 crore to ₹40-50 crore as the company builds its team and marketing infrastructure. Management anticipates these costs will be fully reflected from Q4 onwards, with the sales engine operational by December. Consequently, short-term profitability may dip before recovering, with margins expected to return to above 20% within two to three years.

What the Numbers Show

The acquisition of Minipress XL highlights a strategic focus on high-return, established assets rather than greenfield development. With an implied entry multiple of roughly 14x EBITDA (₹1,250 crore investment vs ₹90 crore EBITDA), the return profile relies heavily on execution-driven margin expansion and volume growth exceeding the current 6.5% CAGR to meet the targeted eight-to-nine-year payback period.

Governance and Ownership

ChrysCapital holds a 70.68% stake in the company following an open offer priced at ₹860.64 per share. The new board includes independent directors with extensive industry experience, such as Ramesh (ex-MD 3M India), Suchita Sharma, and Shashank Sinha (ex-MD Strides Pharma). Management confirmed that trademarks for core brands like Voveran and Methergin have been assigned to the company, while Sandoz brands remain under long-term licensing agreements without future royalties.

Novartis India Limited has dispatched physical letters containing the weblink for its 78th Annual General Meeting (AGM) and the Annual Report for FY26 to shareholders who have not registered their email addresses. The Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited, sent these communications on September 3, 2026.

This physical dispatch complements the electronic distribution completed earlier on September 2, 2026, ensuring all shareholders receive the necessary documentation in compliance with SEBI Listing Regulations.

Dispatch Details

The physical letters were dispatched to members who had not registered their email addresses with the company, any Depository, or the RTA as of the cut-off date of August 25, 2026. The company received confirmation of this dispatch from the RTA on September 4, 2026.

The communication includes the direct weblink to the Annual Report for FY26, available at: https://nilpharma.co.in/pdfs/investors/agm/Novartis%20Annual%20Report_2026.pdf .

AGM Schedule and Voting

The 78th AGM is scheduled for Thursday, September 24, 2026, at 11:00 am. The meeting will be conducted via Video Conferencing or Other Audio-Visual Means.

Remote e-voting will commence on Monday, September 21, 2026, at 9:00 am and conclude on Wednesday, September 23, 2026, at 5:00 pm. Shareholders holding shares as on the cut-off date of Thursday, September 17, 2026, are eligible to vote.

Members attending the AGM who did not cast their votes remotely may vote electronically during the meeting. This process adheres to Section 108 of the Companies Act, 2013, and Regulation 44 of the SEBI Listing Regulations.

Regulatory Compliance and KYC Updates

The intimation regarding the completion of the electronic dispatch was published in Financial Express (English – All editions) and Navshakti (Marathi – Mumbai). The physical dispatch notification was filed with BSE Limited on September 9, 2026.

The letter also serves as a reminder for shareholders holding physical securities to update their KYC details pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024. Shareholders are requested to dematerialise physical securities and update PAN, address, mobile number, bank account details, specimen signature, and nomination choices.

Payments for folios without updated KYC details will only be made electronically with effect from April 1, 2024. Shareholders can access the required forms and circulars at https://web.in.mpms.mufg.com/KYC-downloads.html .